Dalbavancin safety in the phase 2/3 clinical development program

por Seltzer, E, Goldberg, L, Krause, D, Simoneau, D, Boudry, E
Publicado 2008

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment

por Dowell, J, Seltzer, E, Buckwalter, M, Marbury, T, Simoneau, D, Boudry, E
Publicado 2008

Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment

por Dowell, J, Seltzer, E, Stogniew, M, Dorr, MB, Fayocavitz, S, Krause, D, Henkel, T, Marbury, T, Simoneau, D, Boudry, E
Publicado 2008

Novel requirements for HAP2-mediated gamete fusion in Tetrahymena

por Pinello, J.F., Loidl, J., Seltzer, E.S., Cassidy-Hanley, D., Kolbin, D., Abdelatif, A., Rey, F.A., An, R., Newberger, N.J., Bisharyan, Y., Papoyan, H., Byun, H.M., Aguilar, H.C., Cole, E., Clark, T.G.
Publicado 2023